Business
Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference
Media ReleaseCOPENHAGEN, Denmark; May 21, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 2025 Jefferies Global Health Care Conference in New York City, New York at 9:20 EDT (3:20 PM CEST) on June 5, 2025. A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-presentations. About Genmab Genmab is an international biotechnology company with a core purpose of
About this update from Genmab A/s
[{"type":"image","alt":"Genmab A/S","displaySize":"","headline":null,"caption":"Genmab A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3fXMaEmkURmdIw8oGLJV.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d","width":275,"height":85}},"lazy":false},{"type":"text","content":"Media ReleaseCOPENHAGEN, Denmark; May 21, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 2025 Jefferies Global Health Care Conference in New York City, New York at 9:20 EDT (3:20 PM CEST) on June 5, 2025. A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-presentations.","length":418,"tagName":"p"},{"type":"text","content":"About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®.","length":762,"tagName":"p"},{"type":"text","content":"Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.","length":222,"tagName":"p"},{"type":"text","content":"Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate AffairsT: +1 609 524 0065; E: [email protected]","length":178,"tagName":"p"},{"type":"text","content":"Andrew Carlsen, Vice President, Head of Investor RelationsT: +4...